Breast Cancer: Targets and Therapy
Volume 14, 2022 - Issue
Open access
970
Views
9
CrossRef citations to date
0
Altmetric
Review
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Nusayba A BagegniDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA
https://orcid.org/0000-0001-9322-2451
Andrew A DavisDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA
, Katherine K CliftonDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA
& Foluso O AdemuyiwaDivision of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USACorrespondence[email protected]
Pages 113-123
|
Published online: 29 Apr 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.